Imidazoquinolines as dual lipid kinase and mTOR inhibitors
US9370508B2 · kind B2 · utility
12Cited by
0References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 19, 2008 |
| Grant date | Jun 21, 2016 |
| Priority date | — |
| Expiry date | May 19, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the use of compounds of formula (I)in the treatment of mammalian target of rapamycin (mTOR) kinase dependent diseases, methods of use of said compounds in the treatment of said diseases in a warm-blooded animal, especially a human, pharmaceutical preparations comprising said compounds for the treatment of said diseases and said compounds for use in the treatment of said diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.